In this study, we aimed to investigate the clinical utility of serum o-α-synuclein and p-tau181 in differentiating between PSP and PD, to identify diagnostic markers that can be easily assessed in clinical practice. The gene discussed is SNCA; the disease is supranuclear palsy, progressive, 1.